Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
BOULDER, Colo., March 28, 2017 -- Miragen Therapeutics, Inc. (Nasdaq:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today announced that William S. Marshall, Ph.D., President and Chief Executive Officer, will provide a company overview at the Needham and Company 16th Annual Healthcare Conference on Tuesday, April 4, 2017, at 5:00 p.m. ET. The conference is being held at the Westin New York Grand Central hotel in New York City.
The presentation will be webcast live and may be accessed by visiting the "Investors" section of the Company’s web site at www.investors.miragentherapeutics.com. A replay of the webcast will be available for 90 days.
About Miragen Therapeutics, Inc.
Miragen Therapeutics, Inc. is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapeutics with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. miRagen’s two lead product candidates, MRG-106 and MRG-201, are currently in Phase 1 clinical trials. miRagen’s clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155, which is found at abnormally high levels in several blood cancers. miRagen’s clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for miR-29, which is found at abnormally low levels in a number of pathological fibrotic conditions, including cardiac, renal, hepatic, and pulmonary fibrosis, as well as systemic sclerosis. In addition to miRagen’s clinical programs, it is developing a pipeline of pre-clinical product candidates. The goal of miRagen’s translational medicine strategy is to progress rapidly to first in human studies once it has established the pharmacokinetics, pharmacodynamics and safety of the product candidate in pre-clinical studies. For more information, please visit www.miragentherapeutics.com.
For information on clinical trials please visit www.clinicaltrials.gov.
miRagen Investor Contact: Adam Levy Chief Business Officer (720) 407-4595 [email protected]
